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Abstract
Background: A recent controversy in vitamin D research is a “U-shaped association”, with elevated disease risks at
both high and low 25-hydroxyvitamin D (25 (OH) D) levels.
Methods: This is a cross-sectional study of 238 male nursing home veterans in Hawaii. Classification and regression
tree (CART) analysis identified groups based on 25 (OH) D and vitamin D supplementation for frailty risk.
Characteristics were examined and compared across the groups using logistic regression and receiver operating
characteristic (ROC) curve analyses.
Results: CART analysis identified three distinct groups: vitamin D supplement users (n = 86), non-users with low
vitamin D (n = 55), and non-users with high vitamin D (n = 97). Supplement users were the most frail, but had high
mean 25 (OH) D of 26.6 ng/mL, which was compatible with 27.1 ng/mL in non-users with high vitamin D, while mean
25 (OH) D of non-users with low vitamin D was 11.7 ng/mL. Supplement users and non-users with low vitamin D were
significantly more likely to be frail (odds ratio (OR) = 9.90, 95% CI = 2.18–44.86, p = 0.003; OR = 4.28, 95% CI = 1.44–12.
68, p = 0.009, respectively), compared with non-users with low vitamin D. ROC curve analysis showed the three groups
significantly predicted frailty (area under the curve = 0.73), with sensitivity of 64.4% and specificity of 76.7%, while 25
(OH) D did not predict frailty.
Conclusions: In these nursing home veterans, vitamin D supplement users were the most frail but with high 25 (OH)
D. This can potentially be a cause of U-shaped associations between vitamin D levels and negative health outcomes.
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Background
Vitamin D deficiency is prevalent worldwide and has been
recognized as a public health problem [1]. Low vitamin D
has been extensively studied and shown to be associated
with various negative health outcomes, such as osteopor-
osis, fracture, muscle weakness, falls, autoimmune diseases,
and cardiovascular diseases [2]. Optimizing deficient vita-
min D levels with supplementation can result in mostly
favorable results, although definitive evidence from well-
designed randomized controlled clinical trials is lacking [3].
In light of the accumulating evidence on the beneficial ef-
fects of vitamin D supplementation and its relatively safe
side-effect profile, vitamin D supplementation has been rec-
ommended by multiple authorities and guidelines [4–6].
One of the recent controversies in vitamin D research is
a “U-shaped association”, [7–9] in which both high and
low levels of vitamin D are associated with elevated dis-
ease risks [7]. Regarding all-cause mortality, most observa-
tional population-based studies have shown that low
vitamin D predicted premature death, which is supported
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by recent meta-analyses [10–13]. However, there were a
considerable number of studies that showed U-shaped or
reverse J-shaped associations between vitamin D and
mortality [14–20]. One of the meta-analysis studies showed
the possibility that mortality risk may become higher again
at a serum 25-hydroxyvitamin D (25 (OH) D) level of
112.5 nmol/l or more [12]. The association between high
vitamin D and high mortality appears counterintuitive and
the underlying mechanisms are unknown. Criticisms of this
paradoxical finding were that it was due to chance, [7] a lack
of adequate adjustment, [8] an analytical bias due to serum
vitamin D assays, [7] a small number of the highest serum
vitamin D group, [18] or vitamin D intoxication [21].
Use of vitamin D supplementation may be a cause of
increased disease risks at high vitamin D levels and can
create U-shaped associations [22]. The Newcastle 85+
Study prospectively followed 775 men and women aged
85 or older over 6 years and examined all-cause mortality
according to baseline 25 (OH) D levels [13]. Compared
with the middle 25 (OH) D group, the highest and lowest
25 (OH) D groups had non-significantly increased mortal-
ity risks (adjusted hazard ratio [HR] = 1.25, 95% confi-
dence interval [CI] = 0.97–1.63; HR = 1.10, 95%
CI = 0.85–1.42, respectively). After excluding 150 vitamin
D supplement users, the mortality risk for the highest 25
(OH) D group decreased by 16% (adjusted HR = 1.05, 95%
CI = 0.73–1.53) whereas the mortality risk for the lowest
25 (OH) D group increased (adjusted HR = 1.22, 95%
CI = 0.93–1.60) [13]. It is speculated that the supplement
users were at high risk with high 25 (OH) D, likely due to
the supplements, which led to the increased mortality risk
of the highest 25 (OH) D group. Another meta-analysis
study showed that the mortality risk for low 25 (OH) D
was significantly lower among studies with prevalence of
vitamin D supplement use of more than 10% compared
with studies with less than 10% (p for meta-regression
analysis <0.05), [11] which suggests that vitamin D supple-
mentation attenuated inverse association between vitamin
D and mortality, possibly by increasing 25 (OH) D of
high-mortality-risk participants.
In order to further investigate how vitamin D supple-
mentation affects associations between vitamin D status
and health outcomes, we explored use of vitamin D sup-
plementation and serum 25 (OH) D in relation to frailty,
using a cohort of frail nursing home residents [23]
among whom prevalence of both vitamin D supplement
use and vitamin D deficiency are high. Our hypothesis
was that those on a vitamin D supplement were highly
frail even though serum vitamin D levels were elevated
by supplements. They could be included in “high” vita-
min D groups along with healthier vitamin D sufficient
non-supplement users, leading to the seemingly para-
doxically high risks of various health outcomes in those
with high vitamin D.
Methods
Study design, setting, and population
This cross-sectional study was conducted at a Veterans
Affairs nursing home in Honolulu, Hawaii, providing re-
habilitation, skilled-nursing care, intermediate care, res-
pite care, and hospice/palliative care for veterans. The
study participants were all male veterans admitted to the
study nursing home except for those admitted for hos-
pice/palliative care, from 1st of January 2011 to 31st of
December 2012. The data were anonymised and col-
lected by a retrospective chart review. This study was
approved by the Institutional Review Boards of Veterans
Affairs Pacific Islands Health Care System. The study de-
sign, setting, and population have been described in de-
tail elsewhere [24, 25].
Predictor variables - vitamin D supplementation and
vitamin D level
Serum total 25 (OH) D was measured for all veterans on
nursing home admission as a part of initial assessment.
The information on vitamin D supplementation was ob-
tained from transfer summaries, discharge summaries,
outpatient clinic notes, or history taken from veterans or
family. Various dosage, frequency, and duration were ob-
served for vitamin D supplementation, from one multi-
vitamin tab a day to 50,000 IU of ergocalciferol three
times weekly. Use of vitamin D supplementation was
calculated as a mean daily dosage of any vitamin D sup-
plement over the previous 1 month and categorized into
four groups: no supplement, 1–400 IU/day, 401–800 IU/
day, or ≥801 IU/day.
Outcome variable - frailty
Frailty has been described as a state of reduced physio-
logical reserve due to age related accumulation of multi-
system impairments [26]. As people become frailer, they
are more predisposed to increased risks of various ad-
verse health outcomes, including falls, fractures,
hospitalization, nursing home placement, disability, poor
quality of life, and dementia [27–34]. Therefore frailty
was considered as a good surrogate marker of biological
aging [35]. In this study, frailty was measured by using a
deficit accumulation model of the Frailty Index (FI) [35]
FI is calculated from a variety of health deficits that usu-
ally include symptoms, signs, comorbidities, and disabil-
ities that are biologically sensible, accumulate with age,
do not saturate too early, and cover a range of systems
[36]. Although FI does not require the same number of
deficits or the same set of deficits, it is recommended to
include at least 30 deficits [36]. We constructed FI based
on 34 deficits including 12 chronic diseases, 9 psycho-
logical symptoms, 6 functional disabilities, 3 gait/fall-re-
lated problems, 2 cognitive symptoms, 1 obesity, and 1
pain symptom. (see the Additional file 1 for detail) [36,
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37]. Although FI is a continuous score and not meant to
be dichotomized, we used an empirical cut-point to de-
fine frailty as FI > =0.25 [38].
Covariates
Demographic data collected on admission were age,
body mass index, ethnicity (White, Asian/Pacific Is-
lander, or other), education, smoking, alcohol, place
where veterans came from (home, acute care hospitals,
or other nursing homes), season and reason for admis-
sion (rehabilitation, non-rehabilitation skilled-nursing
care, intermediate care, or respite care).
Statistical analysis
The classification and regression tree (CART) analysis
[39] is a non-parametric classification technique that
can deal with multiple predictors of both continuous
and categorical data. It builds a decision tree by recur-
sive partitioning to best explain the risk estimate of the
dependent variable. This method has often been used
for data mining and it was considered to be appropriate
for the exploratory nature of this study. We used this
method to split the cohort based on two variables: use
of vitamin D supplementation and 25 (OH) D, into pro-
gressively smaller and more homogeneous subgroups
with highest discriminative ability of identifying frailty
risk. The minimum number of cases in a node was set
at 23, 1/10 of the entire cohort, and the minimum
change in improvement was set at 0.001. Ten-fold
cross-validation was performed. The subgroups by the
CART analysis were compared for the characteristics
using a one-way analysis of variance (ANOVA) for con-
tinuous variables and a chi-square test for categorical
variables. Correlation coefficient was examined using
Spearman’s rho between 25 (OH) D and the FI in the
entire cohort as well as supplement users and non-
users. Relative likelihood of frailty of each CART group
compared with the entire cohort was calculated. Uni-
variate logistic regression models were used to examine
risk of frailty for the CART groups and other character-
istics. The CART groups were further examined for in-
dependent risk of frailty using a multivariate logistic
regression model adjusted for variables which were sig-
nificant in the univariate logistic regression models.
Frailty risk discrimination by the CART analysis was
assessed using the receiver operating characteristic
(ROC) curve analysis and the area under the ROC
curve (AUC), and was compared with that by 25 (OH)
D as a continuous variable.
Among the supplement users, the characteristics were
compared using a one-way ANOVA for continuous vari-
ables and a chi-square test for categorical variables ac-
cording to the dosage of the supplement.
All statistical analyses were conducted using IBM SPSS
Statistics (version 20, IBM Corporation, Armonk, NY,
USA), and two-sided p value of <0.05 was considered
statistically significant.
Results
There were a total of 302 male veterans admitted to the
study nursing home during 2011 and 2012. Of those, 61
veterans who did not have 25 (OH) D measured within 7
days of admission and 3 veterans who missed more than
30% of deficits for constructing FI were excluded, leaving
238 veterans (78.8%) as a final sample. There were no sig-
nificant differences in mean age, mean 25 (OH) D level,
BMI, smoking, alcohol use and FI between those included
(n = 238) and those excluded (n = 64). Those excluded
had slightly but significantly longer duration of education
compared with those included (13.7 v 13.0 years).
Decision tree analysis
Figure 1 displays a decision tree of the CART analysis.
The cohort was initially divided into two groups: those on
vitamin D supplement of any dosage (1–400 IU/day, 401–
800 IU/day, or ≥801 IU/day, vitamin D supplement users,
n = 86) and those without vitamin D supplement (non-
users, n = 152). Non-users were further divided based on
25 (OH) D with a cut-off point of 17.5 ng/mL into two
groups: non-users with low vitamin D level (n = 55) and
non-users with high vitamin D level (n = 97). The cross-
validation showed the same risk estimate. As a supple-
mentary analysis the CART analysis was repeated using
the FI as a continuous outcome variable, which showed
very similar results (data not shown).
Cohort characteristics
Table 1 presents demographic characteristics of the en-
tire cohort (N = 238). The mean age was 73.4 years. The
mean Frailty Index (FI) was 0.39 and 87.4% (n = 208)
had frailty (FI > =0.25). The mean 25 (OH) D was
23.4 ng/mL, ranging 4–53 ng/mL, and 37.4% (n = 89)
had 25 (OH) D < 20 ng/mL.
The characteristics were compared across three groups
by CART analysis: supplement users (n = 86, 36.1%),
non-users with low vitamin D (n = 55, 23.1%), and non-
users with high vitamin D (n = 97, 40.8%) (Table 1). The
mean FI and prevalence of frailty were both significantly
different across the groups, with supplement users being
the most frail and non-users with high vitamin D being
the least frail (mean FI: 0.43, 0.41, and 0.35, respectively.
Frailty prevalence: 97.7, 90.9, and 76.3%, respectively.
Both p < 0.001). Supplement users and non-users with
high vitamin D had significantly higher 25 (OH) D, 26.6
and 27.1 ng/mL, respectively, than non-users with low
vitamin D, 11.7 ng/mL. While FI and 25 (OH) D were
not significantly correlated in the entire cohort and
Kojima et al. BMC Geriatrics  (2017) 17:236 Page 3 of 9
supplement users (r = −0.10 and −0.05, respectively),
there was a significant inverse correlation between FI
and 25 (OH) D in non-users (r = −0.19, p = 0.02).
Table 2 shows univariate and age-adjusted logistic re-
gression models used to assess risk of frailty (FI ≥ 0.25).
In unadjusted models, supplement users and non-users
with low vitamin D were significantly more likely to be
frail (Odds ratio [OR] = 13.05, 95% CI = 2.98–57.25,
p = 0.001; OR = 3.11, 95% CI = 1.11–8.72, p = 0.03, re-
spectively), with non-users with high vitamin D as a ref-
erence. In age-adjusted models, the risk of frailty for
supplement users and non-users with low vitamin D
remained significant after adjusting for age (OR = 9.90,
95% CI = 2.18–44.86, p = 0.003; OR = 4.28, 95%
CI = 1.44–12.68, p = 0.009, respectively).
Figure 2 shows an ROC curve analysis showing that
CART analysis groups accurately classified risk of frailty
among the entire cohort, with AUC of 0.73
(95%CI = 0.65–0.82, p < 0.001). Being on a vitamin D
supplement, compared with no use, has sensitivity of
64.4% and specificity of 76.7%. Conversely, 25 (OH) D
was not a significant predictor of frailty (AUC = 0.56
95% CI = 0.46–0.66, p = 0.32). After removing supple-
ment users in order to exclude effects of vitamin D sup-
plementation, ROC curve analysis for 25 (OH) D was
repeated only among non-users (n = 152). This repeated
analysis showed that 25 (OH) D significantly predicted
frailty among non-users, with AUC of 0.62 (95%
CI = 0.52–0.73, p = 0.04) (Figure not shown).
Among 86 supplement users, the dosages of vitamin D
supplementation were 1–400 IU/day (n = 27, 31.4%),
401–800 IU/day (n = 38, 44.2%), and ≥801 IU/day
(n = 21, 25.3%). Table 3 compares the three groups and
shows that higher dosage of vitamin D supplementation
was significantly associated with higher 25 (OH) D (p
for trend = 0.003) and higher body mass index
(p = 0.05). Although statistical significance was not
reached, those on higher dosage of supplementation
were more likely from home and less likely from acute
care hospitals (p = 0.06).
Discussion
In the current study, three distinct subgroups were suc-
cessfully identified based on use of vitamin D
Fig. 1 A decision tree by classification and regression tree analysis based on use of vitamin D supplement and 25-hydroxyvitamin D (25 (OH) D)
among 238 male veterans in a nursing home. 25 (OH) D: 25-hydroxyvitamin D
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Table 1 Characteristics according to three groups based on vitamin D level and supplement use
Entire cohort Supplement users Non-users (n = 152)
N = 238 n = 86 (36.1%) Low vitamin D (<18 ng/mL)
n = 55 (23.1%)
High vitamin D (> = 18 ng/mL)
n = 97 (40.8%)
p value
Frailty Index 0.39 ± 0.13 0.43 ± 0.11 0.41 ± 0.13 0.35 ± 0.13 <0.001
Frailty (FI > =0.25) 208 (87.4%) 84 (97.7%) 50 (90.9%) 74 (76.3%) <0.001
25 (OH) D (ng/mL)
Mean 23.4 ± 9.8 26.6 ± 9.3 11.7 ± 3.8 27.1 ± 7.0 <0.001
Range 4–53 6–52 4–17 18–53
< 20 ng/mL 89 (37.4%) 19 (22.1%) 55 (100.0%) 15 (15.5%) <0.001
Age 73.4 ± 13.1 79.0 ± 11.7 67.4 ± 12.1 71.9 ± 13.0 <0.001
Body mass index 26.5 ± 6.7 25.1 ± 6.0 29.5 ± 8.5 26.0 ± 5.5 <0.001
Education (year) 13.0 ± 2.3 13.0 ± 2.4 13.0 ± 3.0 13.0 ± 2.3 1.00
Ethnicity
White 117 (49.2%) 41 (47.7%) 21 (38.2%) 55 (56.7%) 0.03
Asian/Pacific Islander 102 (42.9%) 41 (47.7%) 30 (54.5%) 31 (32.0%)
Others 18 (7.6%) 3 (3.5%) 4 (7.3%) 11 (11.3%)
Smoking
Never 80 (33.6%) 27 (31.4%) 13 (23.6%) 40 (41.2%) 0.10
Past 120 (50.4%) 49 (57.0%) 30 (54.5%) 41 (42.3%)
Current 38 (16.0%) 10 (11.6%) 12 (21.8%) 16 (16.5%)
Alcohol
Never 100 (42.0%) 39 (45.3%) 20 (36.4%) 41 (42.3%) 0.73
Past 83 (34.9%) 30 (34.9%) 22 (40.0%) 31 (32.0%)
Current 55 (23.1%) 17 (19.8%) 13 (23.6%) 25 (25.8%)
Reason for admission
Rehabilitation 86 (36.1%) 26 (30.2%) 24 (43.6%) 36 (37.1%) 0.001
Skilled-nursing care 49 (20.6%) 7 (8.1%) 15 (27.3%) 27 (27.8%)
Intermediate care 8 (3.4%) 4 (4.7%) 1 (1.8%) 3 (3.1%)
Respite 95 (39.9%) 49 (57.0%) 15 (27.3%) 31 (32.0%)
Place veterans came from
Home 101 (42.4%) 54 (62.8%) 15 (27.3%) 32 (33.0%) <0.001
Acute care 128 (53.8%) 28 (32.6%) 38 (69.1%) 62 (63.9%)
Other nursing home 9 (3.8%) 4 (4.7%) 2 (3.6%) 3 (3.1%)
Season of admission
Winter 62 (26.1%) 23 (37.1%) 13 (21.0%) 26 (41.9%) 0.83
Spring 55 (23.1%) 18 (32.7%) 16 (29.1%) 21 (38.2%)
Summer 62 (26.1%) 20 (32.3%) 14 (22.6%) 28 (45.2%)
Autumn 59 (24.8%) 25 (42.4%) 12 (20.3%) 22 (37.3%)
Correlation between FI and
25 (OH) Da
−0.10
p = 0.13
−0.05
p = 0.63
−0.19
p = 0.02
Relative risk of frailty, OR
(95% CI)
1.0 (ref) 1.12 (1.05–1.18)
p < 0.001
1.04 (0.94–1.15)
p = 0.42
0.87 (0.77–0.99)
p = 0.03
Analysis of variance for continuous variables and chi-square test for categorical variables mean ± Standard deviation, n (%)
25 (OH) D 25-hydroxyvitamin D level, 95%CI 95% confidence interval, FI Frailty Index, OR Odds ratio
aSpearman’s correlation coefficient in supplement users and non-users
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Table 2 Univariate and age-adjusted logistic regression models for frailty
Unadjusted Age-adjusted
Factors Odds Ratio (95% CI) p value Odds Ratio (95% CI) p value
Three groups by CART analysis
Non-user with high 25 (OH) D 1.0 (ref) – 1.0 (ref) –
Non-user with low 25 (OH) D 3.11 (1.11–8.72) 0.03 4.28 (1.44–12.68) 0.009
Supplement user 13.05 (2.98–57.25) 0.001 9.90 (2.18–44.86) 0.003
25 (OH) D (ng/mL) 0.98 (0.95–1.02) 0.39 – –
Age (years) 1.06 (1.03–1.10) <0.001 – –
Body mass index 1.01 (0.95–1.07) 0.84 – –
Education (year) 0.90 (0.76–1.08) 0.26 – –
Ethnicity
White 1.0 (ref) – – –
Asian/PI 2.13 (0.92–4.92) 0.08 – –
Others 3.51 (0.44–27.87) 0.24 – –
Smoking
Never 1.0 (ref) – – –
Past 1.59 (0.68–3.74) 0.29 – –
Current 0.94 (0.32–2.73) 0.91 – –
Alcohol
Never 1.0 (ref) – – –
Past 1.12 (0.45–2.81) 0.81 – –
Current 0.70 (0.27–1.78) 0.45 – –
25 (OH) D 25-hydroxyvitamin D level, 95% CI 95% confidence interval, CART Classification and regression tree
Fig. 2 Receiver operating characteristic (ROC) curve analyses for risk of frailty predicted by the classification and regression tree (CART) analysis
groups (blue line) and 25-hydroxyvitamin D (25 (OH) D) level (green line). 25 (OH) D: Serum total 25-hydroxyvitamin D. CART: Classification and
regression tree. Area under the ROC curve (AUC) = 0.73 (95% confidence interval (CI) = 0.65–0.82, p < 0.001) for CART analysis groups (blue line);
AUC = 0.56 (95%CI = 0.46–0.66, p = 0.32) for 25 (OH) D (green line)
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supplementation and 25 (OH) D using the CART ana-
lysis. Taking vitamin D supplementation was the stron-
gest frailty risk discriminative factor, and supplement
users were found to have multiple distinguishable fea-
tures. They were almost all frail, with the highest preva-
lence of 97.7% (84/86) among the three subgroups, but
had high mean 25 (OH) D of 26.6 ng/mL, which was
compatible with non-users with high vitamin D
(27.1 ng/mL). Among supplement users, 25 (OH) D was
not correlated with FI, while there was a significant cor-
relation among non-users.
In light of these findings, we speculate that vitamin D
supplement users are a group of highly frail older people
with paradoxically high 25 (OH) D levels. This discrep-
ancy between 25 (OH) D and frailty may result from the
fact that vitamin D supplementation can quickly correct
low 25 (OH) D [40]; however, it may take longer to see
positive effects on mortality or other outcomes [11, 41].
One meta-analysis showed that vitamin D supplementa-
tion significantly decreased mortality only with follow-up
longer than 3 years [41]. In addition, supplements increase
25 (OH) D more efficiently in those with lower baseline
25 (OH) D, [42] which will further exacerbate the discrep-
ancy. Therefore, frail supplement users are likely to re-
main at high risk of negative health outcomes even with
optimized vitamin D status by supplementation, which
could potentially confound the profiles and outcomes of
the vitamin D-sufficient group. In observational studies,
true associations of 25 (OH) D with outcomes could be at-
tenuated or reversed at high 25 (OH) D levels, creating
falsely null or U-shaped associations unless controlled
properly for the use of vitamin D supplements.
Table 3 Characteristics of vitamin D supplement users according to the dosage
N = 86 1–400 IU/day
(n = 27)
401–800 IU/day
(n = 38)
801+ IU/day
(n = 21)
p value
Frailty Index 0.43 ± 0.11 0.45 ± 0.11 0.40 ± 0.09 0.43 ± 0.12 0.59
Frailty (FI > =0.25) 84 (97.7%) 25 (92.6%) 38 (100.0%) 21 (100.0%) 0.11
25 (OH) D (ng/mL) 26.6 ± 9.3 22.9 ± 8.6 26.8 ± 8.4 30.9 ± 10.2 0.003
Vitamin D deficiency 19 (22.1%) 9 (33.3%) 7 (18.4%) 3 (14.3%) 0.10
Age 79.0 ± 11.7 79.7 ± 9.5 80.9 ± 11.1 74.7 ± 14.6 0.17
Body mass index 25.1 ± 6.0 23.9 ± 4.7 24.7 ± 5.8 27.5 ± 7.5 0.05
Education (year) 13.0 ± 2.4 13.1 ± 1.8 12.7 ± 2.7 13.4 ± 2.7 0.72
Ethnicity
White 41 (47.7%) 13 (48.1%) 22 (59.5%) 6 (28.6%) 0.28
Asian/PI 41 (47.7%) 13 (48.1%) 14 (37.8%) 14 (66.7%)
Others 3 (3.5%) 1 (3.7%) 1 (2.7%) 1 (4.8%)
Reason for admission
Rehabilitation 26 (30.2%) 13 (48.1%) 8 (21.1%) 5 (23.8%) 0.11
Skilled-nursing care 7 (8.1%) 0 (0.0%) 5 (13.2%) 2 (9.5%)
Intermediate care 4 (4.7%) 2 (7.4%) 2 (5.3%) 0 (0.0%)
Respite 49 (57.0%) 12 (44.4%) 23 (60.5%) 14 (66.7%)
Place veterans came from
Home 54 (62.8%) 12 (44.4%) 26 (68.4%) 16 (76.2%) 0.06
Acute care 28 (32.6%) 14 (51.9%) 11 (28.9%) 3 (14.3%)
other nursing home 4 (4.7%) 1 (3.7%) 1 (2.6%) 2 (9.5%)
Smoking
Never 27 (31.4%) 6 (22.2%) 14 (36.8%) 7 (33.3%) 0.75
Past 49 (57.0%) 18 (66.7%) 20 (52.6%) 11 (57.0%)
Current 10 (11.6%) 3 (11.1%) 4 (10.5%) 3 (14.3%)
Alcohol
Never 39 (45.3%) 11 (40.7%) 18 (47.4%) 10 (47.6%) 0.82
Past 30 (34.9%) 11 (40.7%) 11 (28.9%) 8 (38.1%)
Current 17 (19.8%) 5 (18.5%) 9 (23.7%) 3 (14.3%)
One-way ANOVA for continuous variables (p for trend) and chi-square test for categorical variables. mean ± standard deviation, n (%)
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Vitamin D supplements have been used more and
more commonly in general populations. According to
NHANES, the use of dietary vitamin D supplements has
increased among both men and women in most age
groups from 1988 to 1994 to 2003–2006 [43]. This in-
crease may be explained by several reasons. With guide-
lines and authorities advocating the importance of
treating low vitamin D, clinicians more often check pa-
tients’ serum vitamin D levels and prescribe vitamin D
supplement for low vitamin D. Increasing sun protection
for skin cancer prevention can also contribute to the in-
crease in vitamin D supplementation. Due to growing
media exposure regarding risks of low vitamin D levels,
the general public has more awareness of the importance
of vitamin D than ever. Furthermore, vitamin D supple-
ments are inexpensive and readily available over the
counter with almost no serious adverse effects, which
further lowers the threshold for people to start the sup-
plements. In this context, future vitamin D research
should take into account the possibility of high preva-
lence of vitamin D supplementation in various popula-
tions, which may have significant confounding effects.
This study has some limitations and its findings must be
interpreted with caution. First, it included a small number
of only male veterans in a nursing home at a single facility
in Hawaii, and the findings may not be entirely
generalizable to other populations or to women. Second,
some important information related to vitamin D status is
missing, such as dietary vitamin D intake, sunlight exposure,
or reasons for vitamin D supplementation. Third, we did
not have information on what assay was used to measure
25 (OH) D given that 25 (OH) D levels vary according to
the assay used [44]. Fourth, due to the small number of par-
ticipants, we included those who had available data for at
least 70% of the deficits, instead of 80%, which is typically
required for calculation of the FI [36]. Fifth, the multiple
imputation could have been conducted for missing value of
25 (OH) D. Lastly, the cross-sectional study design hinders
assessing prospective associations and interactions among
25 (OH) D, vitamin D supplementation, and health out-
comes, as vitamin D supplementation may improve supple-
ment users’ overall health status and decrease the risks over
years.
Conclusion
Three distinct groups were categorized from the study:
1) vitamin D supplement users, 2) non-users with low
vitamin D, and 3) non-users with high vitamin D levels.
This study shows that use of vitamin D supplements can
potentially be a cause of paradoxical U-shaped associa-
tions between vitamin D levels and negative health out-
comes, by creating a unique group of participants who
are the most frail but have high 25 (OH) D levels. This
highlights the importance of identifying vitamin D
supplement users and ideally obtaining information on
the dosage and duration of the supplementation in order
to better examine the true association between vitamin
D and health outcomes, including frailty status, by con-
trolling for vitamin D supplementation effects. Future
studies can further examine and clarify these effects.
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